74 results about "Inositol phosphate" patented technology

Disclosed in the present invention is a phosphoinositide 3-kinase allosteric inhibitor for treating a disease related to PI3K regulation. Specifically, provided is a compound as represented by formula I or a pharmaceutically acceptable salt thereof. The phosphoinositide 3-kinase allosteric inhibitor of the present invention can effectively conduct allosteric targeted inhibition on a PI3Kα mutation, in particular, a PI3KαH1047R mutation, has relatively good selectivity, and is expected to treat and / or prevent related diseases or disorders.

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.

The invention relates to the technical field of cosmetics, and particularly discloses a composition with after-sun repairing and whitening effects and a preparation method thereof. According to the present invention, various efficient components such as the ergothioneine compound, the acetylchitosamine, the nicotinamide, the sodium hyaluronate, the inositol, the aloe vera extract, the glycerophosphoinositide choline salt, the tetrahydromethylpyrimidine carboxylic acid, the oat beta-glucan compound, the citrus peel extract compound and the skin brightening agent are scientifically matched; according to the present invention, the excellent after-sun repairing and whitening effect is achieved, the comprehensive after-sun skin care is achieved, the skin state can be improved, and the skin health degree can be improved. The application creatively finds that when the glycerophosphoinositide choline salt, the citrus peel extract compound and the skin brightening agent are compounded, the effects of the composition in the aspects of after-sun repairing and whitening can be improved at the same time, and the comprehensive effect is relatively good.

The invention relates to the technical field of biological detection, and discloses an in-situ detection method for the tissue level of a protein and phosphoinositide compound, which comprises the following steps: providing a to-be-detected tissue sample containing the protein and phosphoinositide compound; incubating the sample to be detected by using a primary antibody mixture; incubating a product obtained in the previous step by using a second antibody mixture containing a PLA probe, and reacting to obtain circular DNA (Deoxyribose Nucleic Acid); carrying out in-situ amplification by taking the circular DNA as a template; and acquiring and analyzing a signal of the detection probe. According to the method, the interaction between the protein and the phosphoinositide compound can be specifically detected in situ at the tissue level, the actual state of the protein and the phosphoinositide compound in the physiological and pathological processes of cells can be more truly reflected by the technology, and more accurate information is provided for researching the function and regulation mechanism of the protein and the phosphoinositide compound; wide application prospects are realized.

The invention provides a soothing and repairing composition for dry and sensitive skin as well as a preparation method and application of the soothing and repairing composition, and belongs to the technical field of cosmetics. The soothing and repairing composition is of a liposome structure, cephalin and ceramide-EOP form a cephalin-ceramide complex and serve as a shell layer of the liposome, and plant ecdysone and inositol choline glycerophosphate are wrapped in the liposome; the soothing and repairing composition with the liposome structure has excellent moisturizing, soothing and repairing effects.

Aspects disclosed herein relate to compositions comprising novel phosphoinositide 3-kinase (PI3K) inhibitors, and methods of making the novel PI3K inhibitors. Further, various aspects relate to one or more methods of treating a disease using the compositions disclosed herein, including targeted delivery of the novel PI3K inhibitors disclosed herein.

The present invention relates to salts and crystalline forms of 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, and crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, which are PI3K inhibitors useful in the treatment of cancer and other diseases.

The purpose of the present invention is to provide a novel molded article having antibacterial or antiviral properties, a method for manufacturing the same, and the like. The present invention relates to a molded article 100 which contains a calcium compound 104 and a resin, and has a salt of inositol phosphate 102 with at least one metal element 103 selected from the group consisting of silver, zinc, and copper on a surface 101.

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject:(a) a compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and(b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.

The present invention relates to chemical compounds useful as inhibitors of class II phosphoinositide 3-kinase (PI3K) signaling. The invention further relates to the medical use of inhibitors of class II phosphoinositide 3-kinase (PI3K) signaling in the treatment of medical conditions associated with defective and / or pathological class II phosphoinositide 3-kinase (PI3K) signaling, such as stroke, cardiovascular diseases associated with endothelial cell dysfunction, cancer, cancerometastasis, myopathy and diabetes.

Glycerophosphoinositol (GPI) is used in preventing and treating COVID-19 infections. An environmentally sustainable method is for obtaining glycerophosphoinositol. In particular, a process for preparing glycerophosphoinositol from crude or partially purified phospholipid mixtures, includes in sequence: a) hydrolysis of a crude or partially purified phospholipid mixture by treatment with PLA1 and PLA2 enzymes; b) microfiltration of the mixture from step a) and subsequent ultrafiltration and nanofiltration of the microfiltrate to give a concentrated aqueous fraction of reaction products; c) electrodialysis of the aqueous fraction of step b) for separating ionic compounds from neutral compounds; d) ion exchange chromatography. Moreover, glycerophosphoinositol is used in preventing and treating a COVID-19 syndrome.

The present invention provides heterocyclylamine derivatives of Formula I:wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

The invention relates to the technical field of biomedicine detection, and discloses a tumor cell marker detection system for predicting the activation state of intracellular protein kinase. Comprising a marker detection module used for qualitatively detecting epithelial cell markers, mesenchymal cell markers, cell polarity markers and extracellular matrix related markers in tumor cells; the data processing module is used for performing cross validation on an epithelial cell marker, a mesenchymal cell marker, a cell polarity marker and an extracellular matrix related marker; the dynamic weighting module is used for performing dynamic weighting on different markers based on a complex system theory, and endowing epithelial cadherin with a higher weight; and the judgment module is used for determining whether epithelial intercellular substance transformation occurs or not according to the dynamically weighted marker data, and predicting the activation state of intracellular phosphoinositide 3-kinase alpha and the invasiveness of tumor cells based on the determination result of the epithelial intercellular substance transformation.

The present disclosure provides a soothing repair composition for dry sensitive skin and its preparation method and application, belonging to the technical field of cosmetics. The soothing repair composition of the present disclosure is a liposome structure. Cephalin and ceramide-EOP form a cephalin-ceramide complex, which serves as the shell layer of the liposome. The plant moulting hormone and glycerophosphoinositol choline salt are wrapped inside the liposome. The soothing repair composition with the liposome structure has excellent moisturizing, soothing and repairing effects.

The present invention provides a method for treating cancer in a subject in need thereof, the method comprising administering to the subject: (a) a compound of formula I or a pharmaceutically acceptable salt thereof: wherein R is hydrogen or acyl; and (b) a PD-1 signal transduction inhibitor; wherein the compound of formula I or a pharmaceutically acceptable salt thereof and the PD-1 signal transduction inhibitor are administered in a therapeutically effective combined amount. The present invention also provides a pharmaceutical composition, which comprises a compound of formula I or a pharmaceutically acceptable salt thereof, a PD-1 signal transduction inhibitor, and a pharmaceutically acceptable carrier or excipient.

The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

The present invention provides heterocyclylamine derivatives of Formula I:wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

This invention relates to the field of agricultural fertilizer technology, specifically to a phosphoinositol-chitosan composite organic fertilizer and its preparation method. The organic fertilizer comprises modified phosphoinositol, chitosan graft, humic acid, sugar alcohol chelated zinc, alginate oligosaccharide, bentonite, and a well-rotted organic carrier. Specifically, the modified phosphoinositol and chitosan graft synergistically form a "dual-signal driven" system, effectively activating signaling pathways related to plant root development; the alginate oligosaccharide and sugar alcohol chelated zinc synergistically enhance plant stress resistance; and humic acid and bentonite jointly improve soil structure and achieve slow nutrient release. This organic fertilizer integrates nutrient supply, soil improvement, and physiological regulation, significantly promoting crop root growth, enhancing its resistance to drought, low temperatures, and diseases, and achieving stable yield increases. Furthermore, the raw materials are natural and environmentally friendly, the process is simple, and it is suitable for large-scale production.

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.

The present invention relates to Compounds (A), pharmaceutically acceptable salts thereof, processes for their preparation and their use, optionally in combination with one or more additional therapeutic agents, for the treatment of disease. # imgabs0 #

The present disclosure relates to the use of phosphoinositide 3-kinase (PI3K) inhibitors targeting allosteric and normal pockets of PI3K in methods of treating, preventing, or ameliorating diseases or conditions in which PI3K functions (or in use in treating, preventing, or ameliorating diseases or conditions). The PI3K inhibitors can be used in combination and can target allosteric or normal pockets of PI3K alpha simultaneously, separately, or sequentially. In some aspects of the disclosed methods, PI3K [alpha] inhibitors may target an allosteric or normal pocket of a PI3K [alpha] mutant that is resistant to treatment with another PI3K [alpha] inhibitor that targets a different pocket of PI3K [alpha].

Provided herein are compounds that bind 3-phosphoinositide- dependent protein kinase-1 (ABL1) and / or promote targeted phosphorylation of a substrate. The induced phosphorylation of the target substrate can alter the substrate's structure and function, thus providing compounds which enable phosphorylation of target substrates, including those that may not otherwise be substrates for ABL1, and providing new modes for inducing strategic phosphorylation. Also provided are compounds that are intermediates of the bifunctional compounds. Also provided are compounds that bind an allosteric site of ABL1 and inhibit the phosphorylation of a target substrate. Also provided are pharmaceutical compositions comprising the disclosed compounds and methods of promoting the phosphorylation of target substrates in a biological sample by administering a compound or composition described herein.

The application discloses a pesticide synergist and a preparation method thereof. The pesticide synergist comprises a silanol-initiated polyether shown in formula I, an inositol phosphate-initiated polyether shown in formula II, an alcohol auxiliary agent and water. The silanol-initiated polyether shown in formula I and the inositol phosphate-initiated polyether shown in formula II are synergized, so that the adhesion, spreading, penetration and retention capacity of pesticide droplets on a target surface are significantly enhanced, and the utilization rate of the pesticide is effectively improved. The product has the advantages of low toxicity, environmental friendliness, multi-functional synergism, wide compatibility and the like, the preparation process is simple and stable, and the product is suitable for industrial production.

The disclosure relates to adoptive cell therapy compositions including a population of isolated immune cells that are obtained from a donor subject. The immune cells can be modified to suppress Bruton's tyrosine kinase (BTK), interleukin-2-inducible T cell kinase (ITK), delta isoform of phosphoinositide 3-kinase (PI3Kδ), helios, blimp1, SOCS1, GATA3, IL-10, STAT3, TOX, CD25, foxp3, Ezh2, TGF-beta Receptor II, LAG-3, PD-1, TNF-alpha, or combinations thereof. The immune cells are optionally depleted of CD8+ T cells by about 10-fold or greater relative to un-depleted leukocytes.

This application relates to antibodies or antigen-binding fragments thereof that bind to phosphoinositide-3 -kinase interacting protein 1 (PIK3IP1) protein or antigen-binding fragments, as well as polynucleotides and vectors that encode for such antibodies or antigen-binding fragments. This application further relates to methods of producing the antibodies or antigen- binding fragments and using the antibodies or antigen-binding fragments for treatment of diseases.

The invention discloses an application of a light-induced related protein in detecting phosphoinositide and a kit. According to the invention, it is found for the first time that the light-induced related protein can be specifically combined with phosphoinositide, and the corresponding kit can be designed according to the characteristic so as to realize in-vitro rapid detection of phosphoinositide, thereby providing a new idea for phosphoinositide detection.

The present invention relates to an alkyne derivative, a preparation method for same, and applications thereof in medicine. Specifically, the present invention relates to the alkyne derivative as represented by formula (I), the preparation method for same, a pharmaceutically acceptable salt thereof, and uses of them as a therapeutic agent, specifically as a phosphoinositide 3-kinase γ (PI3Kγ) inhibitor, where the definitions of the substituents in formula (I) are identical to the definitions in the description.

Disclosed herein are methods of treating glioblastoma in a subject comprising, among others, administration of sub-maximal tolerance doses and / or intermittent doses of phosphoinositide 3-kinase (PI3K) inhibitors, autophagy inhibitors and / or checkpoint inhibitors.

The invention discloses a phosphoinositide 3-kinase allosteric inhibitor for treating diseases related to PI3K (phosphoinositide 3-kinase) regulation, and particularly provides a compound shown as a formula I or a pharmaceutically acceptable salt thereof. The phosphoinositide 3-kinase allosteric inhibitor can effectively inhibit PI3K alpha mutation, especially PI3K alpha H1047R mutation in an allosteric targeting mode, has good selectivity and is expected to treat and / or prevent related diseases or obstacles.

Compounds of the following formula:having defined substituents. The compounds can inhibit class II phosphoinositide 3-kinase (PI3K) signaling and are useful for the treatment of a medical condition associated with defective PI3K signaling, such as myopathy, cancer, diabetes, thrombosis or cardiovascular disease.